Join the AUA and SUO on Thursday, April 27 in Chicago for a joint symposium exploring the role of PARP Inhibitor treatments. Mark your calendars, dinner is provided with this FREE program! ➡️ bit.ly/3XAIgvY Ashley Ross MD PhD Kristen R. Scarpato Nancy Davis

Thanks Dr. Cathy Eng Carole Sullivan WSMV 4 Nashville for promoting this important event. #clipin4thecure supports the important #CancerResearch mission of @VUMC_Cancer

🤔For newly diagnosed #cancer #patients it is daunting to identify the best #healthcare provider. Here is MY PERSPECTIVE on why choosing ✔️a @NCIResearchCtr can be the best initial resource. "How to Choose the Best Cancer Care: mysouthernhealth.com/best-cancer-ce…

Great discussion by our very own Dr. Cathy Eng. Dr. Cathy Eng @VUMC_Medicine @VUMC_Cancer youtube.com/live/9NBkN3Suw…

Spinning next Saturday to raise money for cancer research @VUMC_Cancer. Please consider sponsoring me as I try to give my all and not breathe my last breath... give.vanderbilthealth.org/fundraiser/422…

Hot off the press - Updated Amer. Urol. Assn. Society of Urologic Oncology guideline for early detection of #ProstateCancer !

Come join the Vanderbilt team! We are looking for an early/mid-career GU Medical Oncologist with a bladder cancer focus. careercenter.asco.org/job/7618295/vu….

We support and challenge each other. Please reach out with interest or questions!

JUST IN: Belzutifan 005 trial from Merck shows superior PFS/ORR compared ro everolimus ! Results are in ! businesswire.com/news/home/2023…

EV302- enfortumab vedotin and Pembrolizumab met its dual primary endpoints of OS and PFS with ‘clinically meaningful’ improvement versus chemotherapy in patients with previously untreated la/mUC. merck.com/news/merck-ann…

Latest and greatest in GU Oncology 🧡🧡🧡, by the ones really making it happen. GU Oncology Rising ⭐️🌟⭐️🌟⭐️ 👇👇👇👇

New ESMO - Eur. Oncology guidlines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available annalsofoncology.org/article/S0923-…

First-line treatment with Versamune HPV and pembrolizumab met the primary end point of best overall response in the phase 2 VERSATILE-002 trial in HPV6–positive recurrent/metastatic HNSCC.#hnscc #oncology onclive.com/view/first-lin…

Telemedicine Allows for First-of-its-Kind Trial Administering Subcutaneous Immunotherapy at Home Jorge Nieva USC Norris Comprehensive Cancer Center #oncology #MedTwitter #lcsm onclive.com/view/telemedic…

From SWOG Cancer Research Network S1314: Bladder cancer tumors w changes in any of 3 DNA damage-repair genes were >5X as likely to be cleared by neoadj cisplatin-based chemo. Could help ID patients who could trade bladder removal for surveillance. Results in European Urology. swog.org/news-events/ne…

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24

Dr. W. Kimryn Rathmell will step down as Dr. Kimryn Rathmell, effective Monday, January 20. Read Dr. Rathmell’s thoughts in her announcement below.

Congrats Vadim Koshkin MD ✅ 41% ORR pembro retreatment 🕒 Median time between courses: 10.7 mo ⏳ mPFS: 9.5 mo | mOS: 25.7 mo 🔄 65% of responders had CR to first-course 💡 Perhaps some have inherent T effector capacity and require continued PD-1 blockade to maintain response! 🚀

I am at #GU25. Can’t miss the most important GU-directed meeting of the year from ASCO —let us enjoy 3 days of science, clincial advancement and just a wonderful #GU community ! Julie Gralow Clifford Hudis Journal of Clinical Oncology Eric J. Small, MD, FASCO Rana McKay, MD, FASCO Sumanta K. Pal, MD, FASCO Dana-Farber Lank Center for Genitourinary Oncology

Interesting, insightful editorial. ascopubs.org/doi/full/10.12…